Award-Winning Journalist Anjalee Khemlani to Host Virtual Roundtable with Leading Medical Experts to Discuss Latest Developments in Treating Acute Agitation Related to Neuropsychiatric Conditions

Core Insights - The upcoming virtual roundtable hosted by BioXcel Therapeutics will focus on self-administered treatments for acute agitation associated with bipolar disorder and schizophrenia, highlighting the shift in treatment paradigms towards home care [1][3]. Group 1: Event Details - The event is scheduled for December 8, 2025, at 10 a.m. EST and will be hosted by Anjalee Khemlani, a recognized healthcare journalist [2]. - Pre-registration for the event is currently open [2]. Group 2: Industry Context - There are an estimated 57 to 77 million episodes of agitation related to bipolar disorders and schizophrenia occurring annually in the U.S. home setting, indicating a significant need for innovative treatment solutions [3]. - The roundtable aims to provide insights to clinicians, caregivers, investors, and healthcare professionals on how treatment approaches are evolving and what innovations may redefine patient care outside traditional healthcare settings [3]. Group 3: Company Overview - BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, with a focus on drug re-innovation [5]. - The company’s subsidiary, OnkosXcel Therapeutics, is dedicated to developing medicines in immuno-oncology, showcasing its broad therapeutic focus [5].